Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of iPSC-MNP (XS228) in ALS
NCT06765564Phase 1Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Neural Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XS228 in amyotrophic lateral sclerosis (ALS), sponsored by Shanghai East Hospital. Primary endpoints: Adverse Events at 6 months and Serious Adverse Events at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
XS228
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06765564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765564.